ECE2013 Poster Presentations Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) (127 abstracts)
Characteristics and outcomes of the Italian subpopulation enrolled in the observational, multicenter hypopituitary control and complications study (HypoCCS)
Gianluca Aimaretti 1 , Diego Ferone 2 , Maria Rosaria Ambrosio 3 , Paolo Beck-Peccoz 4 , Salvatore Cannavò 5 , Anna Maria Colao 6 , Marco Losa 7 , Beverly Festin Martinez 8 , Paolo Marchi 9 & Alessandra Vottero 9
1Department of Translational Medicine, University of the Eastern Piedmont, Novara, Italy; 2Endocrinology Unit, Department of Internal Medicine and Medical Specialties and Center of Excelence for Biomedical Research, IRCCS AOU San Martino-IST, Genoa, Italy; 3Department of Medical sciences, University of Ferrara, Ferrara, Italy; 4Department of MedicalSciences, Fondazione Policlinico IRCCS, Milan, Italy; 5Department of Clinical and Experimental Medicine – Endocrinology, University of Messina, Messina, Italy; 6University Federico II of Naples, Naples, Italy; 7Department of Neurosurgery, IRCCS San Raffaele, Università Vita-Salute, Milan, Italy; 8Eli Lilly & Co, Indianapolis, USA; 9Medical department, Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy.
Aim: To describe characteristics and outcomes of Italian patients with hypopituitarism participating in HypoCCS.
Methods: Study population was stratified by max GH peak (mGHp) and BMI. Baseline variables included demographic characteristics, type of deficit, smoking habits; variables analyzed over time included weight, Framingham cardiovascular disease (CVD) risk, lipids, GH dose.
Results: Italian subpopulation included 342 patients with mGHp ≤33 (group A); 345 with 33<mGHp≤66 (group B); and 337 with mGHpk >66 percentile (group C) with mean age (years (S.D.)) of 44.2 (16.2), 44. 6 (16.0), 42.6 (15.1), respectively, and adult onset GHD ((%): 75.8, 77.1 and 78.4% respectively). GHD was diagnosed mainly with GHRH+Arginine test (roughly 66% of diagnoses) and percentage of multiple pituitary hormone deficits was higher (P<0.001) in subgroup A (92.7) than in B (85.2) or C (69.5). Patients were equally distributed across normal-, under- and over-weight with average BMI of 28. No differences were detected in smoking habits or in Framingham CVD risk at baseline. More patients in group A than in B or C had hyperlipidemia (n (%): 92 (35.1), 86 (31.1), 69 (24.7) respectively; P=0.029). Mean GH dose at baseline was significantly lower in group A than in B and C (dose/kg (S.D.): 311.0 (162.5), 356.3 (217.9), 391.7 (323.1); P=0.0009) and with a longer treatment duration (years (S.D.): 7.2 (9.2), 5.5 (8.2), 5.0 (7.6); P=0.0014). Analyses over time showed group differences only at certain single time-points. Overall, no significant differences in treatment emergent adverse events (TEAEs) were detected across subgroups, while among the serious TEAEs, only ‘infections and infestations’ were significantly different (n (%): 6 (1.8), 5 (1.5), 0 (0.00); P=0.0406).
Conclusions: Italian patients with mGHp <33 percentile had the worst lipid profile and were given the lower GH treatment dose. The highest percentage of multiple deficits in this group suggests the more severe GHD.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more